v3.25.2
Segment Information (Tables)
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table presents selected financial information about the Company's single operating segment for the three and six months ended June 30, 2025 and 2024 (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2025202420252024
Collaboration revenue$— $357 $— $788 
Program-specific expenses:
Ulixacaltamide18,385 12,045 41,898 23,184 
Vormatrigine17,957 1,860 31,690 2,592 
Relutrigine10,509 1,245 15,886 2,251 
Elsunersen1,317 685 2,078 1,206 
Other early stage assets1,417 1,144 2,522 2,063 
Personnel-related expenses11,913 9,843 24,943 18,110 
Stock-based compensation expense7,770 5,879 16,556 20,354 
Depreciation expense46 107 93 219 
Other segment expenses(a)
6,753 5,037 15,129 10,183 
Interest income4,940 4,811 10,372 7,144 
Net loss$(71,127)$(32,677)$(140,423)$(72,230)
(a) Other segment expenses includes research and development and general and administrative costs not attributable to a specific program